The Claim
Daily supplementation with 375 μg of vitamin MK-7 for three years significantly improves the carboxylation of osteocalcin in postmenopausal women with osteopenia, but does not reduce the rate of bone mineral density loss or alter bone microarchitecture compared to placebo when both groups receive adequate calcium and vitamin D.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In postmenopausal women with osteopenia, taking 375 micrograms of vitamin MK-7 daily for three years increases the carboxylation of osteocalcin, but does not slow bone mineral density loss or change bone microarchitecture when calcium and vitamin D intake is adequate.
See the scientific wording
Daily supplementation with 375 μg of vitamin MK-7 for three years significantly improves the carboxylation of osteocalcin in postmenopausal women with osteopenia, but does not reduce the rate of bone mineral density loss or alter bone microarchitecture compared to placebo when both groups receive adequate calcium and vitamin D.
Vitamin MK-7 activates an enzyme that adds a chemical group to a bone protein, allowing the protein to bind tightly to bone mineral. This makes the protein work better at helping mineral form in bone, but it does not change how fast bone loses mineral over time.
What the research says
1 studyTaking this specific vitamin K2 supplement made a key bone protein work better, but it didn’t stop bones from getting weaker over three years — just like taking calcium and vitamin D alone.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.